Back to Search Start Over

Prevention of risks associated with inappropriate use/unnecessary consumption of medicines

Authors :
Jean-Luc Cracowski
Sophie Muller
Isabelle Anglade
Gilles Bonnefond
Béatrice Bouhanick
Sylvain Bouquet
Sandrine Cabut
Pascale Daynès
Bernard Denis
Dorothée Durand
Annie-Pierre Jonville-Béra
Amir Lahouegue
Magali Léo
Joëlle Micallef
Mathieu Molimard
Catherine Penfornis
Valérie Querol-Ferrer
Source :
Therapie
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Abstract

In the code of public health, misuse is defined as intentional and inappropriate use of a medicine or product, which is not in accordance with the terms of the marketing authorisation or the registration as well as with good practice recommendations. Very often this involves an individual or the interaction of several individuals including the patient, his/her carers, prescriber(s) and/or dispensers. Misuse is common; it is the source of medicinal adverse effects for which a significant part is avoidable. Medicines initially prescribed or dispensed in the context of their marketing authorization (MA) can also be the subject of primary dependency and misappropriation. Companies which develop medicines nationally make declarations to the ANSM (French National Agency for the Safety of Medicines and Health Products) and implement measures to limit non-compliant use of their products. Recently, the coronavirus disease-2019 (COVID-19) pandemic has highlighted the influence and societal impact of drug misuse. The finding of the existence of systemic misuse, the impossibility of proposing simple solutions leads us to propose two main areas for improved information and the training of users and health professionals in medicines in the context of multi-faceted interventions: prevention of misuse on the one hand and its identification and treatment on the other hand.

Details

ISSN :
00405957
Volume :
77
Database :
OpenAIRE
Journal :
Therapies
Accession number :
edsair.doi.dedup.....2f932b542a5de3bfe6e855a4f9c1c023